3D0A Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.79M
Enterprise Value€5.86M
Total Cash (Recent Filing)€975.48K
Total Debt (Recent Filing)€1.32M
Price to Earnings (P/E)―
Beta-24.44
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding100,430,470
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)18.74
Price to Sales (P/S)0.00
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic Platform (TeloView)Owning a focused diagnostic platform provides a durable commercialization pathway: once clinical utility and reimbursement are established, TeloView can generate recurring service or licensing revenue across studies and clinics, supporting multi-year revenue streams tied to adoption rather than one-off products.
Addresses Large, Structural Markets (oncology, Age-related Disease)Targeting oncology and age-related conditions exposes the platform to enduring, growing demand for diagnostics and monitoring. These structural markets offer repeated use cases and long development cycles, so clinical adoption would sustain revenue growth and diversify demand across indications over years.
Lean Operating FootprintA small team and low fixed-cost structure preserve runway and allow focused allocation of scarce resources to product development and commercialization. This operational nimbleness reduces cash required per milestone and supports disciplined execution during multi-quarter commercialization efforts.
Bears Say
No Revenue / Pre-commercial ProfileZero reported revenue and recurring losses indicate the company remains pre-commercial, creating high execution and funding risk. Lack of customer cash flows means progress depends on financing and successful product adoption, making cash predictability and long-term viability uncertain absent clear commercialization milestones.
Negative Shareholders' Equity And Rising DebtNegative equity and increased leverage materially reduce financial flexibility and raise creditor scrutiny. With modest assets, higher debt heightens refinancing and covenant risk, constraining strategic options and increasing the likelihood of dilutive financing or restrictive terms in the near-to-medium term.
Sustained Negative Operating And Free Cash FlowPersistent operating and free cash outflows deplete reserves and force reliance on external funding. This limits capacity to invest in commercialization, clinical validation, or scaling, raising execution risk over the next several quarters and increasing probability of dilutive capital raises if revenues do not materialize.
Telo Genomics Corp News
3D0A FAQ
What was Telo Genomics Corp’s price range in the past 12 months?
Telo Genomics Corp lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Telo Genomics Corp’s market cap?
Telo Genomics Corp’s market cap is €2.79M.
When is Telo Genomics Corp’s upcoming earnings report date?
Telo Genomics Corp’s upcoming earnings report date is Nov 02, 2026 which is in 90 days.
How were Telo Genomics Corp’s earnings last quarter?
Telo Genomics Corp released its earnings results on Jun 02, 2026. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.
Is Telo Genomics Corp overvalued?
According to Wall Street analysts Telo Genomics Corp’s price is currently Overvalued.
Does Telo Genomics Corp pay dividends?
Telo Genomics Corp does not currently pay dividends.
What is Telo Genomics Corp’s EPS estimate?
Telo Genomics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telo Genomics Corp have?
Telo Genomics Corp has 100,430,470 shares outstanding.
What happened to Telo Genomics Corp’s price movement after its last earnings report?
Telo Genomics Corp reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -61.538%.
Which hedge fund is a major shareholder of Telo Genomics Corp?
Currently, no hedge funds are holding shares in DE:3D0A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Telo Genomics Corp
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health conditions. The company's primary innovation is a sophisticated telomere analysis platform, which serves both to diagnose diseases and to forecast patient outcomes. This technology, often integrated with liquid biopsies, provides crucial insights for applications in both cancer and neurological illnesses. Their leading product, Telo-MM, is specifically designed to arm medical professionals with vital, actionable information for effectively managing Multiple Myeloma, a serious blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software system capable of precisely measuring individual patient telomere characteristics. Telo Genomics caters to a broad spectrum of clients, including diagnostic pathologists, clinical doctors, academic researchers, and pharmaceutical developers. A notable endorsement of its technology is a collaborative agreement with the renowned Mayo Clinic, aimed at validating the Telo-MM diagnostic tests for multiple myeloma. Founded in 2014 and based in Toronto, Canada, the company adopted its current name, Telo Genomics Corp., in April 2019, having previously operated as 3D Signatures Inc.
Technical Analysis
BioMark Diagnostics
―
StageZero Life Sciences Ltd
―
Kane Biotech
―
Sona Nanotech Inc
―
Avricore Health
―